Nebenwirkungen · Alprolix
ALPROLIX 250 IU powder and solvent for solution for injection ALPROLIX 500 IU powder and solvent for solution for injection ALPROLIX 1000 IU powder and solvent for solution for injection ALPROLIX 2000 IU powder and solvent for solution for injection ALPROLIX 3000 IU powder and solvent for solution for injection · Abschnitt 4.8 · PDF-Seite 7–8
HOS-135655 · Präparat HOS-097754
7 Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-06T02:00:00Z · SHA-256 e42dd716e190b5b1801370fcbf09f24ba5358dc15bf28247721be9dcc9a1d1b1 · Passage d205bd62c3ac51c492b894c24fa7b454a152c481386f50f72136b9f788e678e7 · Zeichen 5489–5847 im Abschnitt